Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292291 | 0.82 | SMN1; SMN2 (0.42) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL824375 | 0.80 | NPC1 (0.69) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL29531707 | 0.80 | NPC1 (0.69) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL714009 | 0.79 | ALOX5 (0.53) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL15771045 | 0.78 | PTGS2 (0.49) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL693840 | 0.77 | KDM4E (0.54) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL17626062 | 0.77 | ALDH1A1 (0.56) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL11386707 | 0.77 | PTGS2 (0.53) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL693811 | 0.77 | NPC1 (0.48) | NPC1ALDH1A1RAB9AHSD17B10HPGD | |
| SCHEMBL9590894 | 0.76 | PIK3CB (0.43) | NPC1ALDH1A1RAB9AHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | claimed |
| EP-1539739-B1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-24 | — | — | EP | claimed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | claimed |
| JP-2007516200-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1654264-A1 | SPIRO [1-AZABICYCLO [2.2.2]OCTANE-3,5'-OXAZOLIDIN-2'-ONE] DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | claimed |
| WO-2005005435-A1 | SPIRO ′1-AZABICYCLO ′2.2.2!OCTAN-3,5′-OXAZOLIDIN -2′-ONE! DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | claimed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | claimed |
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| EP-1539739-B1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-24 | — | — | EP | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| EP-1718635-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082889-A1 | PIPERIDINYL TARGETING COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-09 | — | — | WO | disclosed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040224986-A1 | Piperidinyl targeting compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-11-11 | — | — | US | disclosed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | NPC1 1817/4885ALDH1A1 1751/4885RAB9A 1193/4885 |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | NPC1 1817/4885ALDH1A1 1751/4885RAB9A 1193/4885 |
| US-20040224986-A1 | Piperidinyl targeting compounds that selectively bind integrins | ITGA5, ITGB5, ITGB1 | NPC1 1159/4885ALDH1A1 1101/4885RAB9A 384/4885 |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | NPC1 1817/4885ALDH1A1 1751/4885RAB9A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.